2026-08-26T12:56:36-05:00 2025-12-31 334358135 SAX ADVISORY LLC 1040 AVENUE OF THE AMERICAS 16TH FLOOR NEW YORK NY 10018 990 2025-01-01 223283911 THE MYELODYSPLASTIC SYNDROMES FOUNDATION MYEL 8006370839 228 PARK AVENUE S PMB 118983 NEW YORK NY 10003 PEGGY ANN TORNEY CEO 8006370839 2026-08-26 1 MIKE SCHALL P02024184 2122682804 2026-08-26 2025 2025-03-06 01:10:19Z MDS FOUNDATION INC PEGGY ANN TORNEY 228 PARK AVENUE S PMB 118983 NEW YORK NY 10003 1859509 0 X WWW.MDS-FOUNDATION.ORG X 1999 NJ DEDICATED TO IMPROVING THE LIVES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) THROUGH SUPPORT, EDUCATION, ADVOCACY, RESEARCH, AND COLLABORATION. 8 7 12 24 0 0 1948899 1828816 0 0 3563 27075 49664 3618 2002126 1859509 354600 165590 0 0 849590 1109957 0 0 529462 1749678 1758477 2953868 3034024 -951742 -1174515 3847112 2623801 257739 208943 3589373 2414858 X THE MDS FOUNDATION IS A GLOBAL NONPROFIT DEDICATED TO IMPROVING THE LIVES OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) THROUGH PATIENT SUPPORT, EDUCATION, ADVOCACY, RESEARCH, AND COLLABORATION TO ADVANCE BETTER CARE AND OUTCOMES WORLDWIDE. 0 0 1464845 THE MDS FOUNDATION ADVOCATES ON BEHALF OF INDIVIDUALS AFFECTED BY MYELODYSPLASTIC SYNDROMES (MDS), A RARE AND COMPLEX BLOOD CANCER. THROUGH EDUCATION, AWARENESS, AND PATIENT ENGAGEMENT, WE EMPOWER PATIENTS AND CAREGIVERS TO MAKE INFORMED HEALTHCARE DECISIONS AND ACCESS APPROPRIATE CARE.WE WORK WITH HEALTHCARE PROFESSIONALS, RESEARCHERS, AND INDUSTRY STAKEHOLDERS TO ENSURE THE PATIENT VOICE IS REPRESENTED IN TREATMENT DEVELOPMENT, POLICY DISCUSSIONS, AND CLINICAL GUIDELINES. WE PROVIDE MULTILINGUAL EDUCATIONAL MATERIALS, PATIENT NAVIGATION SERVICES, PUBLIC AWARENESS CAMPAIGNS, AND REFERRALS TO MDS CENTERS OF EXCELLENCE AROUND THE WORLD. 269674 EDUCATIONAL SYMPOSIA AND A BI-ANNUAL CONFERENCE ARE CONDUCTED IN PARTNERSHIP WITH SEVERAL SOCIETIES AND ASSOCIATIONS, INCLUDING THE AMERICAN SOCIETY OF HEMATOLOGY AND THE ONCOLOGY NURSING SOCIETY. IN ADDITION, THE FOUNDATION HOSTS ITS OWN PROFESSIONAL EDUCATIONAL PROGRAMS DESIGNED TO ADVANCE THE UNDERSTANDING OF MYELODYSPLASTIC SYNDROMES (MDS), IMPROVE THE QUALITY OF PATIENT CARE, AND SUPPORT THE CONTINUING EDUCATION OF HEALTHCARE PROFESSIONALS. THESE INFORMATIVE AND INTERACTIVE PROGRAMS ARE AIMED AT HEMATOLOGISTS, ONCOLOGY NURSES, HEMATOLOGY FELLOWS, PHARMACISTS WORKING WITH MDS PATIENTS, AND OTHER ALLIED HEALTH PROFESSIONALS INVOLVED IN THE CARE AND TREATMENT OF INDIVIDUALS WITH MDS. 316650 165590 THE MDS FOUNDATION SUPPORTS AND ADVANCES SCIENTIFIC RESEARCH IN MYELODYSPLASTIC SYNDROMES (MDS) THROUGH ITS YOUNG INVESTIGATOR RESEARCH PROGRAM. THE FOUNDATION INVITES EARLY-CAREER INVESTIGATORS TO SUBMIT PROPOSALS FOCUSED ON BASIC SCIENCE OR CLINICAL RESEARCH RELATED TO THE CAUSES, EPIDEMIOLOGY, MOLECULAR BIOLOGY, CYTOGENETICS, MORPHOLOGY, PROGNOSIS, AND MANAGEMENT OF MDS.IN ADDITION TO FUNDING INDIVIDUAL RESEARCH, THE FOUNDATION CONVENES INTERNATIONAL WORKING GROUPS COMPOSED OF LEADING SCIENTISTS AND PHYSICIANS TO COLLABORATIVELY IMPROVE DIAGNOSTIC STANDARDS, PROGNOSTIC TOOLS, AND TREATMENT STRATEGIES. 2051169 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 15 0 1 12 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 8 7 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 NJ MA IL TN CA NY X JAMES CHILDRESS PC 3072202892 1740H DELL RANGE BLVD CHEYENNE WY 82009 DR STEPHEN NIMER CHAIRMAN 3.00 X X 0 0 0 LEA HARRISON SECRETARY 40.00 X X 105000 0 2100 SANDY KURTIN TREASURER 4.00 X X 0 0 0 DR PIERRE FENAUX DIRECTOR 1.00 X 0 0 0 DR PETER GREENBERG DIRECTOR 1.00 X 0 0 0 DR LUCA MALCOVATI DIRECTOR 1.00 X 0 0 0 DR MICHAEL SAVONA DIRECTOR 1.00 X 0 0 0 JIM WILLIAMS DIRECTOR 1.00 X 0 0 0 PEGGY ANN TORNEY CEO 40.00 X 228441 0 0 ASHLEY R MONCRIEF PATIENT CARE DIRECTOR 40.00 X 144213 0 0 TANYA RHODES DEVELOPMENT DIRECTOR 40.00 X 112801 0 3465 590455 0 5565 4 0 1 0 COLLOQUY GROUP USA INC 803 WEST BROAD ST FALLS CHURCH VA 22046 COMMUNITY PLATFORM DEVELOPMENT AND MANAG 248400 COLAB HEALTH LTD 78-80 PORTSMOUTH ROAD FIRST FLOOR SURBITON UK KT6 5PT PROGRAM DEVELOPMENT WEBSITE, AND GRANT S 233419 2 48846 363832 1416138 1828816 27075 27075 0 363832 0 0 MISC REVENUE 900099 3618 3618 3618 1859509 0 0 30693 X 165590 165590 335541 210611 56398 68532 631758 291099 109334 231325 4637 1599 945 2093 67068 34730 11502 20836 70953 36742 12168 22043 53198 53198 644203 482693 138177 23333 103139 79808 19046 4285 233044 138990 31188 62866 24813 12902 4219 7692 77012 65819 1716 9477 15 15 269583 264204 3592 1787 14006 7283 2381 4342 PROGRAM DEVELOPMENT 137845 137845 EVENTS 112086 42005 70081 PROFESSIONAL EDUCATION 77957 77957 BAD DEBT 9092 9092 2484 1292 422 770 3034024 2051169 453393 529462 1342465 1022019 1519828 795902 44841 70340 117665 83488 1967835 1315783 815338 652052 6975 0 3847112 2623801 250391 208943 7348 0 257739 208943 X 3589373 1861020 553838 3589373 2414858 3847112 2623801 -1174515 0 X 0 1 X 1 0 X 4284275 3024467 2530463 1948899 1828816 13616920 4284275 3024467 2530463 1948899 1828816 13616920 3623727 9993193 2252 8487 32321 36261 27075 106396 9274 11523 35972 49664 3618 110051 13833367 0.72240 0.75850 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1967835 1315783 652052 652052 X 1859509 0 1859509 0 1859509 3034024 0 3034024 0 3034024 PART X, LINE 2: THE ORGANIZATION DOES NOT BELIEVE ITS FINANCIAL STATEMENTS INCLUDE ANY MATERIAL, UNCERTAIN TAX POSITIONS. TAX FILINGS FOR PERIODS ENDING DECEMBER 31, 2022 AND LATER ARE SUBJECT TO EXAMINATION BY APPLICABLE TAXING AUTHORITIES. BOSTON, MA MOVE FOR MDS 72056 72056 CHICAGO IL MOVE FOR MDS 49992 49992 241784 241784 363832 363832 1 YOUNG INVESTIGATOR GRANTS 3 165590 PART I, LINE 2: THE MDS FOUNDATION, INC.'S YOUNG INVESTIGATOR GRANT PROVIDES AN INVESTIGATOR, EARLY IN THEIR CAREER, THE OPPORTUNITY TO INITIATE, CONTINUE OR COMPLETE A PROJECT THAT FOCUSES ON EITHER BASIC OR CLINICAL MANAGEMENT INTO THE CAUSATION, EPIDEMIOLOGY, MOLECULAR BIOLOGY, CYTOGENETICS, MORPHOLOGY, PROGNOSIS AND TREATMENT OF THE MYELODYSPLASTIC SYNDROMES. THE YOUNG INVESTIGATOR GRANT IS A TWO-YEAR RESEARCH GRANT IN THE AMOUNT OF $150,000, PAID IN TWO EQUAL INSTALLMENTS TO THE AWARDEE'S INSTITUTION. X X 0 0 0 0 0 0 0 0 0 PEGGY ANN TORNEY CEO 228441 0 0 0 0 0 0 0 0 0 228441 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE DRAFT FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND REVIEWED BY THE FOUNDATION'S CEO AND BOARD OF DIRECTORS. PRIOR TO SUBMISSION TO THE IRS, THE FORM 990 IS FORMALLY REVIEWED AND APPROVED BY THE CHAIRMAN OF THE BOARD, THE FINANCE COMMITTEE, AND THE CEO. THE FINAL VERSION IS DISTRIBUTED TO THE FULL BOARD FOR REVIEW AND COMMENT TO ENSURE ACCURACY AND TRANSPARENCY BEFORE IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS AND SUBMITS A DISCLOSURE OF RELATIONSHIPS STATEMENT TO THE MANAGEMENT OF MDS FOUNDATION, INC. ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15A THE BOARD PERFORMS A SALARY COMPARABILITY ANALYSIS USING THE 990 INFORMATION FOR SIMILAR NONPROFIT ORGANIZATIONS. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 NO DOCUMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART IX, LINE 11G CONSULTANTS: PROGRAM SERVICE EXPENSES 134,038. MANAGEMENT AND GENERAL EXPENSES 86,102. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 220,140. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 348,655. MANAGEMENT AND GENERAL EXPENSES 52,075. FUNDRAISING EXPENSES 23,333. TOTAL EXPENSES 424,063.